The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate

Completed · Phase 4

Conditions studied: Chronic Kidney Disease

In brief

The purpose of this study is to study the effects of Paricalcitol (Zemplar) on kidney functioning. The investigators hypothesize that the increase in serum creatinine observed in recent paricalcitol trials is a function of reduced creatinine secretion and not an actual reduction in kidney function. 16 patients will have kidney function measured via iothalamate clearance at baseline, after 7 days of paricalcitol treatment and after 7 days of being washed off the paricalcitol.

Key facts

Study ID

NCT01163162

Run by

Indiana University

People needed

16

Starts

2010-08-01

Expected to finish

2011-06-01

Last updated by the study team

2013-05-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > 18 years
• Stage 3 or 4 CKD
• Ability to give informed consent

You may not qualify if…

• Serum Calcium > 10 g/dL
• Serum Phosphorous > 6 g/dL
• On > 400 units/d Vitamin D therapy
• Receiving cimetidine, triamterene, or trimethoprim, drugs that block creatinine secretion
• On vitamin D receptor activators (paricalcitol, calcitriol or Zemplar)
• Allergic to radiocontrast dye

Where it is running

• Roudebush VA Medical Center — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.